NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Interventional Procedures Advisory Committee

Minutes of the Committee's **170th** meeting held at 10:30 on **14th June 2018** at NICE, 10 Spring Gardens, London, SW1A 2BU.

PRESENT:

Dr Tom Clutton-Brock (Chair)

Dr Wael Agur Mrs Sally Brearley Dr Nicholas Chalmers Mr Mahmoud Elfar Mrs Rosemary Harris Mr Anthony Hatswell

Mr Colin Howie
Mr Alistair Jenkins
Mr Malcolm Lowe-lauri

Dr Neil McGuire Mr Kieran Murphy Mr Frank Smith Dr Dhiraj Tripathi Dr James Tysome

In Attendance NICE Staff:

Mrs Bijal Joshi - Programme Manager, IPP

Mrs Helen Gallo- Analyst, IPP

Professor Kevin Harris - Programme Director Clinical Advisor, IPP

Miss Chloe Kastoryano - Public Involvement Adviser, PIP Professor John Powell, Consultant Clinical Advisor, IPP Ms Deonee Stanislaus – Administrator (Temp), IPP

Mrs Vassilia Verdiel - Analyst IPP Mrs Lakshmi Mandava- Analyst IPP

Observers: Sophia Lee

Apologies: Dr Andrew Cook

Dr Chris Carroll

Dr Anthony Emmerson Mr Jonathan Anderson

Dr Peter Murphy Mr Tim Jackson Dr Tim Kinnaird Dr Zahida Adam Dr Neil Mcquire

Note: The order in which the Committee took items of business at the meeting might differ from the agenda

Introduction to the meeting

The Chairman welcomed the Committee Members and observers.

Sophia Lee was welcomed as an observer. She is doing an internship at NICE.

Bijal Joshi – Programme Manager has returned from maternity leave.

Deonee Stanislaus – Administrator will be leaving NICE.

The Chairman also welcomed the members of the public and company representatives present at the meeting.

Code of conduct for members of the public and company representatives attending the meeting

The Chairman outlined the code of conduct for the members of the public and company representatives attending the meeting.

1. Any Other Business

Mark Campbell will be the Acting Programme Director whilst Mirella Marlow will be covering a different team.

Meindert Boysen has been appointed as Centre Director.

Outstanding annual declarations of interest forms which to be completed today and returned to Administrator.

Previous Committee Member Stephen Large has been honoured at the recent NHS hero's awards.

David Haslam has been knighted in Queen's birthday honours for his services to NHS Leadership.

2. <u>Minutes of previous meeting</u>

Members accepted these as a correct record except for the following:

Page 8 – Title of brief spelt incorrectly. Thomas Clutton-Brock advised that this correction has already been made.

3. Matters arising

None

4. Agenda changes

The chairman informed the Committee that the ordering of agenda items is correct.

5. NICE's Advisory Body guide to declaring a conflict of interest

The Chairman drew the Committee's attention to NICE's advisory body quick guide for declaring conflicts of interest.

6. Newly Notified Procedures

IP1043 - Transcranial MRI guided focused ultrasound thalamotomy for neuropathic pain

The discussion on IP1043 - Transcranial MRI guided focused ultrasound thalamotomy for neuropathic pain started at 10:46.

Kieran Murphy declared a direct financial interest in a competitor product for this procedure and therefore left for the discussion and did not participate in the decision making.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Anthony Hatswell and Alistair Jenkins

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at **11:08**.

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1043 Transcranial MRI guided focused ultrasound thalamotomy for neuropathic pain ended at 11:34.

Kieran Murphy and members of the public as well as company representatives returned at 11:37.

IP1097/2 - Platelet-rich plasma injections for osteoarthritis of the knee

The discussion on IP1097/2 - Platelet-rich plasma injections for osteoarthritis of the knee started at 11:37.

Colin Howie declared that he has a colleague involved in research related to this IP. This was considered an indirect interest and he was allowed to stay for the discussion and decision making.

Anthony Hatswell declared that he was a co-author on two abstracts on the cost effectiveness of glucosamine for treating osteoarthritis (2011 and 2013). As this was more than 12 months before he joined the committee it was not considered a conflict of interest. . He was allowed able to stay for the discussion and decision making.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by James Tysome and Colin Howie

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 12:17.

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1097/2 - Platelet-rich plasma injections for osteoarthritis of the knee ended at 12:43.

The members of the public as well as company representatives returned at 13:22.

7. Public Consultation comments

IP395/2 - Intravesical microwave hyperthermia and chemotherapy for superficial bladder cancer

The discussion on IP395/2 - Intravesical microwave hyperthermia and chemotherapy for superficial bladder cancer did not go ahead due to an administrative error with the collation of public consultation comments.

IP 1192 - Leadless cardiac pacemaker implantation for bradyarrhythmias The discussion on IP - 1192 Leadless cardiac pacemaker implantation for bradyarrhythmias started at 13:22.

No conflicts of interest were declared for this procedure

No other conflicts of interest were declared.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock

The Committee considered the consultation comments and made changes to sections 3.7, 1.2, 2.2, 2.3, 2.4, 3.6, 1.5 and lay box in part 1.

The following study, identified during consultation, will be added to the main table of the Overview:

Mollengarden D, Goldberg K, Wong D, and Roehrborn C (2017) Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer & Prostatic Diseases 27, 27

Tjong et.al.,Leadless pacemaker versus transvenous single chamber pacemaker therapy: a propensity matched analysis. Heart Rhythm, 2018, April 27 (635 patients, of which 254 leadless and 381 transvenous

Yarlagadda et.al., Safety and feasibility of leadless pacemaker in patients undergoing atrioventricular node ablation for atrial fibrillation. Heart Rhythm 2018, Mar 1 (127 patients, of which 60 leadless and 67 transvenous)

4Garweg C, Ector J, Voros G, et al. (2017) Monocentric experience of leadless pacing with focus on challenging cases for conventional pacemaker Acta Cardiologica: 1-10. (Replace study 8)

Tjong FVY, Knops RE et al 92018). midterm safety and performance of a leadless cardiac pacemaker: 3 year follow-up to the leadless trial (Nanostim safety and performance trial of a leadless cardiac pacemaker system). Circulation 137:633-35. (add 3 year data to study 1)

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at **14:18**.

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP - 1192 Leadless cardiac pacemaker implantation for bradyarrhythmias ended at 14:40.

The members of the public as well as company representatives returned to the meeting at 14:42.

IP865/2 - Sutureless Aortic Valve Replacement for aortic stenosis

The discussion on IP865/2 - Sutureless Aortic Valve Replacement for aortic stenosis started at 14:43.

No conflicts of interest were declared for this procedure

No other conflicts of interest were declared.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by **Tom Clutton-Brock**

The Committee considered the consultation comments and made changes to sections 2.3, 2.4, 3.7, 3.1, 1.3 and a title change.

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 15:05.

The Committee then made changes to section.

The Committee upheld its decision on the safety and efficacy of the procedure

The discussion on IP865/2 - Sutureless Aortic Valve Replacement for aortic stenosis ended at 15:10.

The members of the public as well as company representatives returned to the meeting at 15:11.

IP1567 - Superior rectal artery embolisation for haemorrhoids

The discussion on IP1567 - Superior rectal artery embolisation for haemorrhoids started at 15:12.

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Nicholas Chalmers

The Committee considered the consultation comments.

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1567 - Superior rectal artery embolisation for haemorrhoids ended at 15:22.

The members of the public as well as company representatives returned to the meeting at 15:24.

IP1555 - Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

The discussion on IP1555 - Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia started at 15:24.

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Mahmoud Elfar

The Committee considered the consultation comments and made changes to sections 2.2 and 2.3

The following studies, identified during consultation, will be added to the main table of the Overview:

Gupta N, Rogers T, Holland B et al. (2018) 3-year treatment outcomes of water vapor thermal therapy (Rezum System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. Journal of Urology 27, 27

Mollengarden D, Goldberg K, Wong D, and Roehrborn C (2017) Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer & Prostatic Diseases 27, 27

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 15:41.

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1555 Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia ended at 15:43.

8. Briefs of procedures for future assessment

IP1709 - Laser treatment for an anal fistula

The discussion on IP1709 - Laser treatment for an anal fistula started at 15:44.

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Tom Clutton–Brock declared he is a co-recipient of a grant from the NIHR into a treatment for anal fistula. This was considered a non-financial professional and personal conflict of interest.

Introduced by Tom Clutton-Brock

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1709 - Laser treatment for an anal fistula ended at 15:52.

IP1703 - Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence following removal of the colon and rectum.

The discussion on IP1703 - Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence following removal of the colon and rectum started at 15:52.

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

No conflicts declared

Introduced by Tom Clutton-Brock

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1703 Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence following removal of the colon and rectum ended at 15:58.

IP1718 - High intensity focused ultrasound ablation for symptomatic benign thyroid nodules

The discussion on IP1718 - High intensity focused ultrasound ablation for symptomatic benign thyroid nodules started at 15:58.

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

No conflicts declared

Introduced by Nicholas Chalmers

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1718 - High intensity focused ultrasound ablation for symptomatic benign thyroid nodules ended at 16:10.

10. <u>Date of the next meeting</u>

The **171th** meeting of the Interventional Procedures Advisory Committee will be held on **Thursday 12 July 2018**, and will start promptly at 10:30. The meeting will be held at **NICE**, **10 Spring Gardens**, **London**, **SW1A 2BU**.

The meeting ended at 16:10.